Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection
MMWR. Morbidity and Mortality Weekly Report·
- DOI
- 10.15585/mmwr.mm6725a5
- PMID
- 29953429
- PMCID
- PMC6023184
- OpenAlex
- W2811025390
- Study type
- Systematic review
- Publisher
- Centers for Disease Control MMWR Office
- Article type
- journal-article
- Integrity
- current
Why this research matters now
Broadening access to highly adherent preventive therapies supports national objectives to interrupt pathogen transmission and reduce disease burden across varied demographic groups.
Structured evidence summary
Research question
How should federal guidelines adapt the once-weekly isoniazid-rifapentine protocol for preventing active tuberculosis, particularly regarding age restrictions and supervision requirements?
Study design
The authors conducted a systematic review and meta-analysis evaluating existing literature before formulating revised federal treatment directives.
Population and setting
The analysis targets residents within the United States carrying asymptomatic mycobacterial infections, specifically extending coverage to pediatric cohorts and immunocompromised individuals.
Main findings
Aggregated data demonstrated comparable safety and therapeutic outcomes relative to established alternatives, alongside markedly improved medication adherence. These results prompted expanded eligibility criteria and authorized unsupervised dosing protocols.
Public-health relevance
Broadening access to highly adherent preventive therapies supports national objectives to interrupt pathogen transmission and reduce disease burden across varied demographic groups.
Important limitations
This summary relies exclusively on the submitted abstract and metadata, requiring the original publication for decision-grade interpretation.
GIDS interpretation
Classified under health policy and infectious disease management, this record serves as a reference for tracking regulatory shifts in antimicrobial prophylaxis rather than generating novel epidemiological data.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 10 auditable classifier relationships to diseases, places, topics, and study design.